United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 3.8mg/1ml solution for injection vials (aspen pharma trading ltd - dexamethasone sodium phosphate - solution for injection - 3.8mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 6.6mg/2ml solution for injection vials (pfizer ltd - dexamethasone sodium phosphate - solution for injection - 3.3mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 3.3mg/1ml solution for injection ampoules (wockhardt uk ltd - dexamethasone sodium phosphate - solution for injection - 3.3mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 3.3mg/1ml solution for injection ampoules (pfizer ltd - dexamethasone sodium phosphate - solution for injection - 3.3mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - dexamethasone sodium phosphate - oral solution - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - dexamethasone sodium phosphate - oral solution - 4mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - dexamethasone sodium phosphate, quantity: 4.37 mg/ml - injection, solution - excipient ingredients: sodium citrate; disodium edetate; sodium sulfite; water for injections; sodium hydroxide; hydrochloric acid - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in: ? acute adrenocortical insufficiency - addison?s disease, bilateral adrenalectomy; ? relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available; ? primary and secondary adrenocortical insufficiency. disease therapy: dexamethasone is indicated for therapy of the following diseases: collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy. pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency. blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia. rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis. skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localized neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis. gastrointestinal disorders: ulcerative colitis, regional enteritis. oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis). eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy. neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children. endocrine disorders: adrenal insufficiency. preoperative and postoperative support: dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery. shock: dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - dexamethasone phenylpropionate; dexamethasone sodium phosphate - parenteral liquid/solution/suspension - dexamethasone phenylpropionate steroid-glucocorticoid active 2.0 mg/ml; dexamethasone sodium phosphate steroid-glucocorticoid active 1.0 mg/ml - endocrine system - cat | cattle | dog | goat | horse | pigs | sheep | beef | billy | bitch | boar | bos indicus | bos taurus | bovine | buck | buff - anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle soreness | osteoarthritis | platelet activity | rheumatism | sprains | strains | tendon sprains | traumatic swelling

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - dexamethasone sodium phosphate - oral solution - 400microgram/1ml

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - a. intravenous or intramuscular administration. when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: post-traumatic osteoarthritis synovitis of osteoarthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) acute and subacute bursitis epicondylitis acute nonspecific tenosynovitis acute gouty arthritis psoriatic arthritis ankylosing spondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus acute rheumatic carditis 4. dermatologic diseases pemphigus severe erythema multiforme (stevens-johnson syndrome) exfoliative dermatitis bullous dermatitis herpetiformis severe seborrheic dermatitis severe psoriasis mycosis fungoides 5. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: bronchial asthma contact dermatitis atopic dermatitis serum sickness seasonal or perennial allergic rhinitis drug hypersensitivity reactions urticarial transfusion reactions acute noninfectious laryngeal edema (epinephrine is the drug of first choice) 6. ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye, such as: herpes zoster ophthalmicus iritis, iridocyclitis chorioretinitis diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmia anterior segment inflammation allergic conjunctivitis allergic corneal marginal ulcers keratitis 7. gastrointestinal diseases to tide the patient over a critical period of the disease in: ulcerative colitis (systemic therapy) regional enteritis (systemic therapy) 8. respiratory diseases symptomatic sarcoidosis berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy loeffler's syndrome not manageable by other means aspiration pneumonitis 9. hematologic disorders acquired (autoimmune) hemolytic anemia idiopathic thrombocytopenic purpura in adults (i.v. only; i.m. administration is contraindicated) secondary thrombocytopenia in adults erythroblastopenia (rbc anemia) congenital (erythroid) hypoplastic anemia 10. neoplastic diseases for palliative management of: leukemias and lymphomas in adults acute leukemia of childhood 11. edematous states to induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 12. nervous system acute exacerbations of multiple sclerosis 13. miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy trichinosis with neurologic or myocardial involvement diagnostic testing of adrenocortical hyperfunction cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management. b. intra-articular or soft tissue administration.when the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intra-articular or soft tissue administration are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis rheumatoid arthritis acute and subacute bursitis acute gouty arthritis epicondylitis acute nonspecific tenosynovitis post-traumatic osteoarthritis c. intralesional administration.when the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intralesional administration are indicated for: keloids localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis) discoid lupus erythematosus necrobiosis lipoidica diabeticorum alopecia areata they also may be useful in cystic tumors of an aponeurosis tendon (ganglia). systemic fungal infections.